NCT04526717View on ClinicalTrials.gov

Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

December 31, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions

Covid19

Interventions

DRUG

MPT0B640

Each dose of MPT0B640 will be administrated per Cohort. (15, 30, 60, 80, 100 mg of MPT0B640)

Sponsors

Lead Sponsor

All Listed Sponsors

lead

J Ints Bio

INDUSTRY